Based on current treatment standards, most patients would receive CDK4/6 inhibitors in a first- or second-line setting at our institution; nevertheless, our results confirm that there is a subgroup of patients with metastatic HR+/HER2− breast cancer who can achieve a durable response with ET alone. This evidence concerns the gene CDK4 and breast cancer.